The FDA: protector or puppet?
Terpening
C M
CM
Department of Pharmacy Practice, University of Florida, Gainesville 32601, USA.
D002839:Chromans / Q000009:adverse effects; D020117:Cisapride / Q000009:adverse effects / Q000627:therapeutic use; D004335:Drug and Narcotic Control / Q000331:legislation & jurisprudence; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects; D013844:Thiazoles / Q000009:adverse effects; D045162:Thiazolidinediones; D019460:Tobacco Industry / Q000331:legislation & jurisprudence; D000077288:Troglitazone; D014481:United States; D014486:United States Food and Drug Administration / Q000331:legislation & jurisprudence*
D002839:Chromans; D007004:Hypoglycemic Agents; D013844:Thiazoles; D045162:Thiazolidinediones; D000077288:Troglitazone; D020117:Cisapride